Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Study summary

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedDomvanalimab and Quemliclustat

Plus 3 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 1, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Active Not Recruiting

The study is underway but is not accepting new participants.

What kind of study?Phase 2

Interventional

Where is it offered?53 U.S. locations

Locations may change over time.

Who runs it?Gilead Sciences

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Gilead Sciences
Interventions being studied: Drug: Domvanalimab; Drug: Quemliclustat; Drug: Zimberelimab; Drug: Docetaxel; Drug: Platinum-Based Doublet

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Treatment approach

Immunotherapy→Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Histologically or cytologically documented Stage IV metastatic, NSCLC
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1
At least one measurable target lesion per RECIST v1.1.
Adequate organ function
Participants must be willing to provide adequate tumor tissue

Reasons someone may not be able to joinExclusion criteria

Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Investigational Product(s) (IPs) hazardous
Use of any live vaccines against infectious diseases within 28 days of first dose of IP(s).
Use of supra-physiologic doses of corticosteroids (\> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications ≤ 14 days before the initiation of study treatment (absorbable topical corticosteroids are not excluded).
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy NOTE: Other protocol defined Inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of Alabama at Birmingham (UAB)Birmingham, Alabama
University of California San Diego (UCSD)La Jolla, California
Memorial Cancer Institute at Memorial Regional HospitalHollywood, Florida
Hematology Oncology Associates Of The Treasure CoastPort Saint Lucie, Florida
Florida Cancer Specialists (Administration and Drug Shipment)The Villages, Florida
Northwestern Memorial HospitalChicago, Illinois
Ochsner Clinic FoundationJefferson, Louisiana
Henry Ford HospitalDetroit, Michigan
Virginia Cancer Specialists, PCFairfax, Virginia
Medical Oncology Associated, PS (dba Summit Cancer Centers)Spokane, Washington
The Border Cancer HospitalAlbury, New South Wales
Pindara Private HospitalBenowa, Queensland

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 1, 2026. Always confirm current availability with the study team.

View original record ↗